Control of Inflammation and Sustained Improvements in Patient‐Reported Outcomes in Patients With Psoriatic Arthritis: Bimekizumab Two‐Year Results From Two Phase 3 Studies

Ähnliche Einträge

• Efficacy and Safety of Bimekizumab in Patients With Psoriatic Arthritis With or Without Methotrexate: 52‐Week Results From Two Phase 3 Studies
  von: Iain B. McInnes, et al.
  Veröffentlicht: (2024)
• What Matters in Psoriatic Arthritis: A Comparison of Patient and Clinician Perspectives
  von: Philip J. Mease, et al.
  Veröffentlicht: (2025)
• What Clinical Factors Affect Length of Transition to Psoriatic Arthritis in Patients With Psoriasis?
  von: Shashank Cheemalavagu, et al.
  Veröffentlicht: (2024)
• Association Between Achievement of Clinical Disease Control and Improvement in Patient‐Reported Outcomes and Quality of Life in Patients With Psoriatic Arthritis in the Phase 3 SELECT‐PsA 1 and 2 Randomized Controlled Trials
  von: Arthur Kavanaugh, et al.
  Veröffentlicht: (2024)
• Improvements in Patient‐Reported Outcomes Through Six Months of Guselkumab Treatment in Patients With Active Psoriatic Arthritis: Real‐World Data From the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
  von: Philip J. Mease, et al.
  Veröffentlicht: (2024)